Small Molecules

Carvedilol

Quality Solutions

Category: Cardiovascular



USP can support your development and manufacturing activities on Carvedilol-based medicines with these existing and upcoming standards.

Authorized Distributor

Official and Proposed Documentary Standards and Associated Physical Materials

MONOGRAPH 1

CARVEDILOL Official as of 01-Jan-2021	
USP Carvedilol RS	USP-1096622
USP Carvedilol Related Compound A RS	USP-1096633
USP Carvedilol Related Compound B RS	USP-1096644
USP Carvedilol Related Compound C RS	USP-1096655
USP Carvedilol Related Compound D RS	USP-1096666
USP Carvedilol Related Compound E RS	USP-1096677
USP Carvedilol System Suitability Mixture RS	USP-1096688

MONOGRAPH 2

CARVEDILOL TABLETS | *NEW* Official as of 01-Aug-2023	
USP Carvedilol RS	USP-1096622
PHARMACEUTICAL ANALYTICAL IMPURITY(IES)*	
USP N-Isopropylcarvedilol PAI I *NEW*	USP-1A00230
USP Carvedilol Related Compound H PAI I *NEW*	USP-1A00890
USP N-Nitroso Carvedilol Solution (1 mL (1mg/mL)) PAI I *NEW*	USP-1A04210

[#] Pharmaceutical Analytical Impurities (PAI products) are released using a process developed by USP's subject matter experts. The release process is based on internal policies, standard operating procedures, and requirements as defined by USP's Quality Management System. USP is an ISO 9001:2015 certified facility. PAI products are different from official USP Reference Standards. PAI products are not required for compendial compliance.